Otsuka (OTCMKTS:OTSKY) Sees Unusually-High Trading Volume – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares saw unusually-high trading volume on Wednesday . Approximately 35,632 shares traded hands during mid-day trading, a decline of 12% from the previous session’s volume of 40,304 shares.The stock last traded at $33.69 and had previously closed at $33.88.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Otsuka Stock Performance

The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $36.29 billion and a price-to-earnings ratio of 14.25. The stock has a fifty day moving average price of $34.54 and a 200-day moving average price of $33.05.

Otsuka (OTCMKTS:OTSKY) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.